Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives

Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. Despite substantial in vitro cytotoxicity, response rates in early clinical trials with 4-HPR have been less than anticipated, likely due to the low bioavailability of the initial oral capsule formulation....

Full description

Saved in:
Bibliographic Details
Published in:Experimental biology and medicine (Maywood, N.J.) N.J.), 2017-06, Vol.242 (11), p.1178-1184
Main Authors: Cooper, Jason P, Reynolds, C Patrick, Cho, Hwangeui, Kang, Min H
Format: Article
Language:English
Subjects:
Administration, Oral
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - pharmacology
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Fenretinide - administration & dosage
Fenretinide - adverse effects
Fenretinide - pharmacokinetics
Fenretinide - pharmacology
Humans
Infusions, Intravenous
Lymphoma, T-Cell - drug therapy
Neuroblastoma - drug therapy
Pharmacology and Toxicology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. Despite substantial in vitro cytotoxicity, response rates in early clinical trials with 4-HPR have been less than anticipated, likely due to the low bioavailability of the initial oral capsule formulation. Several clinical studies have shown that the oral capsule formulation at maximum tolerated dose (MTD) achieved
ISSN:1535-3702
1535-3699
DOI:10.1177/1535370217706952